Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2006-05-16
2006-05-16
Swartz, Rodney P (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S009100, C424S009200, C424S184100, C424S185100, C424S234100, C435S041000, C435S243000, C530S300000, C530S350000
Reexamination Certificate
active
07045134
ABSTRACT:
Immunologically invisible carrier molecules connect a plurality of copies of an immunologically active molecule in an immunologic assay.
REFERENCES:
patent: 4970300 (1990-11-01), Fulton
patent: 5187065 (1993-02-01), Schutzer
patent: 5219564 (1993-06-01), Zalipsky
patent: 5455027 (1995-10-01), Zalipsky
patent: 5545698 (1996-08-01), Barany
patent: WO 91 13630 (1991-09-01), None
patent: WO 97 42221 (1997-11-01), None
Bar, Fritz W., et al., “New Biocompatible Polymer Surface Coating for Stents Results in a Low Neointimal Response,”J. Biomedical Materials Research2000; 52:193-198.
Becker, Timothy A., “Calcium Alginate Gel: A Biocompatible and Mechanically Stable Polymer for Endovascular Embolization,”J. Biomedical Materials Research2001; 54:76-86.
Buchko, Christopher J. et al., “Surface Characterization of Porous, Biocompatible Protein Polymer Thin Films,”Biomaterials2001; 22:1289-1300.
Buron, F., et al., “BOP: Biocompatible Osteoconductive Polymer: An Experimental Approach,”Clinical Materials1994; 16:217-221.
Ershov, I.A., et al., “Polymer Biocompatible X-Ray Contract Hydrogel for Esophageal Vein Obstruction in Portal Hypertension,”Med. Tekh.1994; 2:37-40. (Russian. See translation of Findings attached to article.).
Haisch, A., et al., “Tissue Engineering of Human Cartilage for Reconstructive Surgery Using Biocompatible, Resorbable Fibrin Glue with Polymer Structures,”HNO1996; 44:624-629. (German. English abstract on p. 625.).
Isobe, Masatsugu et al., “Bone Morphogenetic Protein Encapsulated with a Biodegradable and Biocompatible Polymer,”Journal of Biomedical Materials Research1996; 32:433-438.
Iwasaki, Yasuhiko et al., “Semi-interpenetrating Polymer Networks composed of Biocompatible Phospholipid Polymer and Segmented Polyurethane,”Journal of Biomedical Materials Research2000; 52:701-708.
Langer, R., “Biomaterials in Drug Delivery,”Accounts of Chemical Research.Nov. 2, 2000; 33:94-101.
Langer, R., “Tissue Engineering,”Molecular TherapyJan. 2000; 1:12-15.
Polous, Y. M., et al., “The Application of the Biocompatible Antimicrobic Polymer Film for the Prevention of Intestinal Suture Incompetence Under Conditions of Peritonitis,”Vest. Khir. Im. II Grek1985; 134:55-57. (Greek. English abstract on p. 57.).
Qiu, Bo et al., “Selection of Continuous Epitope Sequences and Their Incorporation into Poly(Ethylene Glycol)-Peptide Conjugates for Use in Serodiagnostic Immunoassays: Application to Lyme Disease,”Biopolymers2000; 55:319-333.
Raudino, Antonio et al., “Binding of Lipid Vesicles to Protein-Coated Solid Polymer Surfaces: A Model for Cell Adhesion to Artificial Biocompatible Materials,”Journal of Colloid and Interface Science2000; 231:66-73.
Barbour, “The Biological and Social Phenomenon of Lyme Disease”, 260 Science 1610 (1993).
Brunner, “Immune Complexes from Serum of Patients with Lyme Disease ContainBorrelia burgdorferiAntigen and Antigen-Specific Antibodies: Potential Use for Improved Testing”, 182 J. of Infectious Diseases 534 (2000).
Brunner, “Immunoglobulin M Capture Assay for Serologic Confirmation of Early Lyme Disease: Analysis of Immune Complexes with BiotinylatedBorrelia burgdorferiSonicate Enhanced with Flagellin Peptide Epitope”, 36 J. Clin. Micro. 1074 (1998).
Brunner, “New Method for Detection ofBorrelia burgdorferiAntigen Complexed to Antibody in Seronegative Lyme Disease”, 249 J. Immunol. Methods 185 (2001).
Bückmann, “Functionalization of Poly(ethylene glycol) and Monomethoxy-Poly(ethylene glycol)”, 182 Makromol Chem. 1379 (1981).
Ervin, “The Bell Tolls for the Infectious Diseases Clinician”, 153 J Inf Dis 183 (1986).
Frank, “Spot Synthesis: An Easy Technique for the Positionally Addressable, Parellel Chemical Synthesis on a Membrane Support”, 48 Tetrahedron 9217 (1992).
Geckeler, “Functionalization of Soluble Polymers”, 1 Polym. Bull 427 (1979).
Geysen, “Use of Peptide Synthesis to Probe Viral Antigens for Epitopes to a Resolution of a Single Amino Acid”, 81 Proc. Natl. Acad. Sci. 3998 (1984).
Gilmore, “Outer Surface Protein C (OspC), but not p39, is a Protective Immunogen Against a Tick-TransmittedBorrelia burgdorferiChallenge: Evidence for a Conformational Protective Epitope in OspC”, 64 Infection and Immunity 2234 (1996).
Jungblut, “Proteomics in Human Disease: Cancer, Heart and Infectious Diseases”, 20 Electrophoresis 2100 (1999).
Magnarelli, “Cross Reactivity of Nonspecific Treponemal Antibody in Serologic Tests for Lyme Disease”, 28 J. Clin. Microbiol. 1276 (1990).
Mathiesen, “The Dominant Epitope ofBorrelia gariniiOuter Surface Protein C Recognized by Sera from Patients with Neuroborreloisis Has a Surface-Exposed Conserved Structural Motif”, 66 Inf. And Immun. 4073 (1998).
Mathiesen, “Peptide Based OspC Enzyme-Linked Immunosorbent Assay for Serodiagnosis of Lyme Borreliosis”, 36 J. Clin. Microbiol. 3474 (1998).
Qiu, “Studies on Polymers for Biomedical Applications: . . . ”, (Dissertation, Oct. 1999) (unpublished).
Schneider, “Prognostic B-Cell Epitopes on the Flagellar Protein ofBorrelia burgdorferi”, 60 Inf and Immun. 316 (1992).
Sigal, “The Lyme Disease Controversy”, 156 Arch. Intern. Med 1493 (1996).
Sigal, “Pitfalls in the Diagnosis and Management of Lyme Disease”, 41 Arthritis & Rheumatism 195 (1998).
Sigal, “The Polymerase Chain Reactioon Assay forBorrelia burgdorferiin the Diagnosis of Lyme Disease”, 120 Annals Intern. Med. 520 (1994).
Sigal, “A Vaccine Consisting of RecombinantBorrelia burgdorferiOuter-Surface Protein A to Prevent Lyme Disease”, 339 New Engl. J. Med. 216 (1998).
Simpson, “Antibody to a 39-KilodaltonBorrelia burgdorferiAntigen (P39) as a Marker for Infection in Experimentally and Naturally Inoculated Animals”, 29 J. Clin Microbiol 236 (1991).
Simpson, “Nucleotide Sequence and Analysis of the Gene inBorrelia burgdorferiEncoding the Immunogenic P39 Antigen”, 119 Fed of Europ. Microbiol. Soc.s Letters 381 (1994).
Simpson, “Reactivity of Human Lyme Borreliosis Sera with a 39-Kilodalton Antigen Specific toBorrelia burdgorferi”, 28 J. Clin Microbiol 1329 (1990).
Yu, “Multi-Well ELISA Based on Independent Peptide Antigens for Antibody Capture”, 198 J. Immunol. Meth. 25 (1996).
Yu, “Presentation of Peptide Antigens as Albumin Conjugates for Use in Detection of Serum Antibodies by Enzyme-Linked Immunosorbent Assay”, 7 Bioconjugate Chem. 338 (1996).
Zalipsky, “Attachment of Drugs to Polyethylene Glycols”, 19 Eur. Polym. J. 1177 (1983).
Zalipsky, “Esterification of Polyethylene Glycols”, A21 J Macromol. Sci.-Chem. 839 (1984).
Zalipsky, “Functionalized Poly(ethylene glycol) for Preparation of Biologically Relevant Conjugates”, 6 Bioconjugate Chem. 150 (1995).
Brunner Michael
Katz Michael
Qiu Bo
Sigal Leonard
Stein Stanley
Perkins Coie LLP
Swartz Rodney P
University of Medicine and Dentistry of New Jersey
LandOfFree
Borellia burgdorferi epitope peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Borellia burgdorferi epitope peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Borellia burgdorferi epitope peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3552810